key: cord-0820231-mzw34tft authors: Ye, Zhicheng; Dong, Niuniu; Liang, Keqing; Hu, Haixia; Xu, Jin title: Analytical and clinical evaluation of a novel assay for measurement of interleukin 6 in human whole blood samples date: 2021-09-20 journal: J Clin Lab Anal DOI: 10.1002/jcla.24011 sha: ccd026c6f43914c6235b873cb56a6d9f92024f95 doc_id: 820231 cord_uid: mzw34tft BACKGROUND: Interleukin 6 assays are useful in early detection of infections and risk stratification of critically ill patients, so an assay with a short turnaround‐time and near‐patient use is preferred. This study evaluated the performance of a new interleukin 6 assay, Pylon IL‐6 assay, and explored its potential use in near‐patient settings. METHODS: We carried out imprecision, linearity and comparison studies using serum and plasma samples according to CLSI EP guidelines. The stability of whole blood samples during storage was assessed. Furthermore, whole blood samples from pediatric patients with suspected infection were measured to evaluate the assay's diagnostic performance. RESULTS: The within‐run CVs and total CVs of Pylon IL‐6 assay were determined as 1.8% and 3.0% at 159.3 pg/ml and 3.5% and 4.7% at 8009.9 pg/ml, respectively. The method showed linearity between 1.5 and 42,854 pg/ml. The results of serum samples measured by Pylon assays correlated to those measured by Roche assays, as well as to those of matched whole blood samples measured by Pylon assays. IL‐6 in whole blood was found stable for ~8 h at room temperature. Pylon IL‐6 results of whole blood samples from 179 pediatric patients with suspected infection showed an AUC of 0.842 in diagnosis of bacterial infection. The turnaround time of Pylon IL‐6 assay was only 1 h when using whole blood samples. CONCLUSION: The new assay demonstrated performance comparable to those performed on clinical laboratory instruments and can be used in near‐patient settings with whole blood to reduce turnaround times. Interleukin 6 (IL-6) is a pleiotropic cytokine produced by various stromal cells and immune system cells, involved in inflammation and infection responses, regeneration process, metabolism regulation, bone homeostasis, and neural functions, etc. 1 It is indicated in many diseases such as infection, injury, trauma, stress, neoplasia, postsurgery complications, and chronic inflammatory diseases. 2 In outpatient departments and emergency department (ED), IL-6 is useful for screening bacterial infection and sepsis in febrile patients and predicting later complications in trauma patients. 3, 4 In intensive care units (ICU), IL-6 levels are useful in evaluating severity of systemic inflammatory response syndrome and sepsis and predicting outcomes of patients. 5, 6 In the current COVID-19 pandemic, a high level of IL-6 at the admission predicts ICU placement and poor outcomes. 7 A short turnaround time (TAT) from sample collection to results report of IL-6 assays can facilitate patient management in those clinical settings. However, most IL-6 assays are only available on large laboratory-based instruments using plasma or serum samples with prolonged TATs. 8 Here, we evaluated a new Pylon IL-6 assay performed on a benchtop immuno-analyzer that can use whole blood (WB) samples, and explored its usability in near-patient settings to reduce TATs for improvement in patient care. The study evaluated the performance of the Pylon IL-6 assay (ET Healthcare, China) based on a cyclic enhanced fluorescent immunoassay performed on a fully automated, benchtop Pylon 3D immunoanalyzer. A description of assay procedures is available elsewhere. 9 In brief, the assay format is a unitized test strip containing wells with pre-dispensed reagents. A quartz-glass probe tip coated with capture antibodies moves between wells to capture sample IL-6 and form immune complexes with detection antibodies, before fluorescent polymers are bounded to the immune complexes on the tip through biotin and streptavidin interaction. After measuring fluorescence bound on the probe tip, the IL-6 concentration is derived from a reagent lot specific calibration curve. The whole assay process is completed by Pylon 3D immuneanalyzer automatically in about 10 min after patients' blood collection tubes and Pylon test strips are loaded in the analyzer. When measuring WB samples, the analyzer's pipetting subsystem senses hematocrit at each sampling from individual collection tubes and a software algorithm corrects for hematocrit in WB before the WB results are reported. Two pooled serum samples supplemented with IL-6 (~150 and ~8000 pg/ml) were aliquoted and stored at −80°C. For five consecutive days, an aliquot from each sample was thawed and measured in triplicate. Within-run and total analytical imprecision was calculated according to CLSI EP 15-A2. A low-concentration pool was prepared using patients' samples close to limit of detection. A high-concentration pool was prepared by spiking recombinant IL-6 (Sigma Aldrich, product no. I1395) into an aliquot of the pooled sample to a final concentration of ~45,000 pg/ ml. Six different analyte concentrations were prepared by directly mixing the low-concentration and high-concentration sample pool in the ratios of 5:0, 4:1, 3:2, 2:3, 1:4, and 0:5. Samples of each concentration was measured in duplicates. Similarly, linearity was also evaluated using five patients' serum samples of various concentrations. The results were analyzed according to CLSI EP 6A. A total of 100 remnant serum samples from outpatients and ED patients were measured by the Pylon assay and the Elecsys IL-6 assay on a Cobas e 602 (Roche). To compare the results of different sample types, EDTA-anticoagulated WB samples were tested against matched serum samples using the Pylon assay. All the samples were stored at 4°C and measured within 8 h of collection. Passing-Bablok regressions were used for analysis. Ten WB samples from patients (concentration range, 50-3000 pg/ ml) were divided into 2 vials each and stored at room temperature and 4°C respectively up to 72 h. The initial concentrations of the samples were determined and the samples were measured after 1, 2, Pediatric patients, admitted to the ED department of the Children's Statistical analyses were performed with MedCalc. All hypothesis testing was two-tailed and p values of <0.05 were considered to indicate statistical significance. The Pylon IL-6 assay had a within-run CV of 1.8% and a total CV of 3.0% at a mean concentration of 159.3 pg/ml (pool 1) and a withinrun CV of 3.5% and a total CV of 4.7% at a mean concentration of 8009.9 pg/ml (pool 2). The low-concentration pool had a mean IL-6 level of 1.5 pg/ml, while the high concentration pool had a mean of 42,854 pg/ml. Thus, the method was linear within 1.5-42,854 pg/ml. The results of 100 serum samples measured by the Pylon assay The results of the stability study were shown with IL-6 values dis- WB samples had recovery rates of less than 90%. The samples of a total of 179 pediatric patients (107 males, 59.8%) in the ED were included. The median age of these patients was It is noticed that IL-6, CRP, and PCT levels of the group of bacterial infections showed more pronounced increased than the group of F I G U R E 1 Linearity study using recombinant IL-6 showed to best fit with first-order model (1.5-42,854 pg/ml) virus infections (Table 1) IL-6 is known for its use in assessing patients with suspected infection or sepsis. 3 During the outbreak of the COVID-19, its use in risk F I G U R E 2 Correlations (Passing-Bablok) between the Pylon and Elecsys IL-6 assay (A) and between Pylon serum and WB results (B). Inserts are the correlation of samples lower than 100 pg/ml F I G U R E 3 Stability study of IL-6 in 10 WB samples at room temperature (A) and 4°C (B). Recovery rates were calculated as percentages of baseline concentrations. Box-and-whisker plots showed the distribution of recovery rates across 10 samples at each time points. The red dash line is the recovery rate of 90% stratification of ED and ICU patients is more relevant. 10 Thus, an IL-6 assay with a short TAT is preferred especially in ED, ICU, and outpatient departments, while most IL-6 assays performed in the clinical laboratories had prolonged TATs. 8 In this study, we evaluated a new Pylon IL-6 assay for the potential to reduce TAT and use in nearpatient settings. The within-run CVs and total CVs of the assay were less than 5% in the imprecision study. The assay showed linearity over a wide concentration range (1.5-42,854 pg/ml), which is much wider than the detection range of the Elecsys IL-6 assay (1.5-5000 pg/ml). In conclusion, the new Pylon IL-6 assay demonstrated comparable performance to those assays performed on clinical laboratory instruments. Further, the feature of WB sampling offers advantages in ED or other near-patient settings where TAT is critical. We thank the laboratory members for their contributions to this study. The authors declare that they have no conflicts of interest. The pro-and anti-inflammatory properties of the cytokine interleukin-6 IL-6 in inflammation, immunity, and disease Interleukin-6 improves infection identification when added to physician judgment Age, median (IQR b ) IQR: Interquartile Range. c comparison between groups using Kruskal-Wallis test. d comparison between groups using Chi-squared test. during evaluation of potentially septic patients Using IL-6 concentrations in the first 24 h following trauma to predict immunological complications and mortality in trauma patients: a meta-analysis Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis Is Interleukin-6 a better predictor of successful antibiotic therapy than procalcitonin and Creactive protein? A single center study in critically ill adults High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19 Test ID: IL6, Interleukin 6, Plasma Mayo Foundation for Medical Education and Research Performance characteristics of a high-sensitivity cardiac troponin assay using plasma and whole blood samples Interleukin-6 in Covid-19: a systematic review and meta-analysis